Trial · NCT05633407
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version) | Efgartigimod | -14.369 | Standard Deviation 15.2541 | score on a scale | |
| Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version) | Placebo | -15.957 | Standard Deviation 17.2963 | score on a scale | |
| Change From Baseline to Week 24 in the MaPS | Efgartigimod | -23.5 | Standard Deviation 25.87 | score on a scale | |
| Change From Baseline to Week 24 in the MaPS | Placebo | -19.8 | Standard Deviation 27.75 | score on a scale | |
| Number of Participants With TEAEs and TESAEs | Efgartigimod | TEAEs | 31 | Participants | |
| Number of Participants With TEAEs and TESAEs | Placebo | TEAEs | 14 | Participants | |
| Number of Participants With TEAEs and TESAEs | Efgartigimod | TESAEs | 0 | Participants | |
| Number of Participants With TEAEs and TESAEs | Placebo | TESAEs | 0 | Participants | |
| Percentage of Participants With Improved PGI-S at Week 24 | Efgartigimod | 1-week recall | 45.5 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Week 24 | Placebo | 1-week recall | 53.3 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Week 24 | Efgartigimod | 2-week recall | 54.5 | percentage of participants | |
| Percentage of Participants With Improved PGI-S at Week 24 | Placebo | 2-week recall | 33.3 | percentage of participants | |
| Percentage of Participants With Improved in PGI-C at Week 24 | Efgartigimod | 65.4 | percentage of participants | ||
| Percentage of Participants With Improved in PGI-C at Week 24 | Placebo | 53.3 | percentage of participants | ||
| Change From Baseline to Week 24 in the PROMIS Fatigue Short Form 8a | Efgartigimod | -9.5 | Standard Deviation 8.77 | T-score | |
| Change From Baseline to Week 24 in the PROMIS Fatigue Short Form 8a | Placebo | -7.0 | Standard Deviation 9.40 | T-score | |
| Change From Baseline to Week 24 in the PROMIS Cognitive Function Short Form 6a | Efgartigimod | 3.9 | Standard Deviation 9.58 | T-score | |
| Change From Baseline to Week 24 in the PROMIS Cognitive Function Short Form 6a | Placebo | 6.7 | Standard Deviation 9.74 | T-score | |
| Percent Change From Baseline in Total IgG Levels at Week 24 | Efgartigimod | -69.341 | Standard Deviation 6.0637 | percent change | |
| Percent Change From Baseline in Total IgG Levels at Week 24 | Placebo | 5.868 | Standard Deviation 13.1379 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05633407/results